---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-007650"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T09:11:31.863172+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock Q1 net loss $74.7M; BLA priority review set for Sept 22, 2025; cash to 2027

## Summary
- Net loss $74.7M ($0.67 per share) vs $56.9M in Q1 2024; no revenue.
- Cash, equivalents, securities $364.4M as of March 31, 2025; expected to fund into 2027.
- FDA accepted BLA for apitegromab with priority review; PDUFA date Sept 22, 2025.
- Topline results from Phase 2 EMBRAZE obesity trial expected June 2025.
- Leadership: David Hallal CEO; Akshay Vaishnaw President R&D; Keith Woods COO; Vikas Sinha CFO.

## SEC filing metadata
- accession: 0001558370-25-007650
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000155837025007650/0001558370-25-007650-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000155837025007650/srrk-20250514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-007650
- JSON: https://secwatch.observer/filing/0001558370-25-007650.json
- Plain text: https://secwatch.observer/filing/0001558370-25-007650.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.